



ASX / Media Release  
20 January 2025

## Invex Receives £114k R&D Tax Rebate from UK Government

---

**Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company)** a biopharmaceutical company focused on the development and commercialisation of Exenatide for neurological conditions relating to raised intracranial pressure (ICP) today announces the receipt of £114k (approximately A\$0.22 million) to the Company's wholly owned UK subsidiary from the UK government for eligible R&D expenditures made by Invex during the 2024 financial year.

- ENDS -

*This release dated 20 January 2025 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.*

---

**For more information, please contact:**

**Company/Investors**

Dr Thomas Duthy  
Executive Director  
[tduthy@invextherapeutics.com](mailto:tduthy@invextherapeutics.com)  
+61 402 493 727

**Media**

Margie Livingston  
Ignite Communications  
[margie@ignitecommunications.com.au](mailto:margie@ignitecommunications.com.au)  
+61 438 661 131

To subscribe to Invex email alerts, please visit [www.invextherapeutics.com](http://www.invextherapeutics.com) and follow us on Twitter **@InvexThera\_ASX**

## About Invex Therapeutics Ltd

---

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. [www.invextherapeutics.com](http://www.invextherapeutics.com).